Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophrenia
Interventions
Iloperidone, Ziprasidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 28 more
Terminated Phase 3 Interventional Results available

A Study of LY2140023 in Patients With Schizophrenia

NCT01307800
Conditions
Schizophrenia
Interventions
LY2140023, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Wichita, Kansas
Conditions
Schizophrenia
Interventions
Placebo, Emraclidine 10 mg, Emraclidine 30 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more
Conditions
Schizophrenia
Interventions
RGH-188
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Schizophrenia
Interventions
Oxytocin, Inactive placebo nasal spray
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis

NCT01981356
Conditions
Psychotic Disorders
Interventions
Acceptance and Commitment Therapy, Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Schizophrenia
Interventions
N-Acetylcysteine, Placebo
Dietary Supplement · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia
Interventions
Cariprazine, Aripiprazole, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 17 more
Conditions
Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania, Manic State, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 48 more
Conditions
Schizophrenia
Interventions
SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 29 more
Conditions
Schizophrenia
Interventions
LB-102 (50 mg tablet), LB-102 (100 mg tablet), Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 9 more
Conditions
Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders, Anxiety Disorder
Interventions
Group Music Therapy Advocacy Recording Intervention (MTAR)
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Belle Mead, New Jersey
Conditions
Schizophrenia
Interventions
vabicaserin, risperidone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more
Conditions
Schizophrenia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Wallingford, Connecticut
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Quetiapine, escitalopram, Sertraline, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia
Interventions
Emraclidine 15 mg, Emraclidine 30 mg, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more
Conditions
Schizophrenia
Interventions
RBP-7000, Placebo, Risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
32
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
25
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more
Conditions
Schizophrenia
Interventions
TAK-063 20 mg, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more
Conditions
Psychosis; Acute
Interventions
risperidone, aripiprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Schizophrenia
Interventions
ALK3831, Olanzapine, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 13 more
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Paliperidone Palmitate
Combination Product · Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 13 more